Search for "synthetic strategy" in Full Text gives 292 result(s) in Beilstein Journal of Organic Chemistry. Showing first 200.
Beilstein J. Org. Chem. 2019, 15, 1722–1757, doi:10.3762/bjoc.15.168
Graphical Abstract
Figure 1: Examples of three-carbon chirons.
Figure 2: Structures of derivatives of N-(1-phenylethyl)aziridine-2-carboxylic acid 5–8.
Figure 3: Synthetic equivalency of aziridine aldehydes 6.
Scheme 1: Synthesis of N-(1-phenylethyl)aziridine-2-carboxylates 5. Reagents and conditions: a) TEA, toluene,...
Scheme 2: Absolute configuration at C2 in (2S,1'S)-5a. Reagents and conditions: a) 20% HClO4, 80 °C, 30 h the...
Scheme 3: Major synthetic strategies for a 2-ketoaziridine scaffold [R* = (R)- or (S)-1-phenylethyl; R′ = Alk...
Scheme 4: Synthesis of cyanide (2S,1'S)-13. Reagents and conditions: a) NH3, EtOH/H2O, rt, 72 h; b) Ph3P, CCl4...
Scheme 5: Synthesis of key intermediates (R)-16 and (R)-17 for (R,R)-formoterol (14) and (R)-tamsulosin (15)....
Scheme 6: Synthesis of mitotic kinesin inhibitors (2R/S,1'R)-23. Reagents and conditions: a) H2, Pd(OH)2, EtO...
Scheme 7: Synthesis of (R)-mexiletine ((R)-24). Reagents and conditions: a) TsCl, TEA, DMAP, CH2Cl2, rt, 1 h;...
Scheme 8: Synthesis of (−)-cathinone ((S)-27). Reagents and conditions: a) PhMgBr, ether, 0 °C; b) H2, 10% Pd...
Scheme 9: Synthesis of N-Boc-norpseudoephedrine ((1S,2S)-(+)-29) and N-Boc-norephedrine ((1R,2S)-29). Reagent...
Scheme 10: Synthesis of (−)-ephedrine ((1R,2S)-31). Reagents and conditions: a) TfOMe, MeCN then NaBH3CN, rt; ...
Scheme 11: Synthesis of xestoaminol C ((2S,3R)-35), 3-epi-xestoaminol C ((2S,3S)-35) and N-Boc-spisulosine ((2S...
Scheme 12: Synthesis of ʟ-tryptophanol ((S)-41). Reagents and conditions: a) CDI, MeCN, rt, 1 h then TMSI, MeC...
Scheme 13: Synthesis of ʟ-homophenylalaninol ((S)-42). Reagents and conditions: a) NaH, THF, 0 °C to −78 °C, 1...
Scheme 14: Synthesis of ᴅ-homo(4-octylphenyl)alaninol ((R)-47) and a sphingolipid analogue (R)-48. Reagents an...
Scheme 15: Synthesis of florfenicol ((1R,2S)-49). Reagents and conditions: a) (S)-1-phenylethylamine, TEA, MeO...
Scheme 16: Synthesis of natural tyroscherin ((2S,3R,6E,8R,10R)-55). Reagents and conditions: a) I(CH2)3OTIPS, t...
Scheme 17: Syntheses of (−)-hygrine (S)-61, (−)-hygroline (2S,2'S)-62 and (−)-pseudohygroline (2S,2'R)-62. Rea...
Scheme 18: Synthesis of pyrrolidine (3S,3'R)-68, a fragment of the fluoroquinolone antibiotic PF-00951966. Rea...
Scheme 19: Synthesis of sphingolipid analogues (R)-76. Reagents and conditions: a) BnBr, Mg, THF, reflux, 6 h;...
Scheme 20: Synthesis of ᴅ-threo-PDMP (1R,2R)-81. Reagents and conditions: a) TMSCl, NaI, MeCN, rt, 1 h 50 min,...
Scheme 21: Synthesis of the sphingolipid analogue SG-14 (2S,3S)-84. Reagents and conditions: a) LiAlH4, THF, 0...
Scheme 22: Synthesis of the sphingolipid analogue SG-12 (2S,3R)-88. Reagents and conditions: a) 1-(bromomethyl...
Scheme 23: Synthesis of sphingosine-1-phosphate analogues DS-SG-44 and DS-SG-45 (2S,3R)-89a and (2S,3R)-89a. R...
Scheme 24: Synthesis of N-Boc-safingol ((2S,3S)-95) and N-Boc-ᴅ-erythro-sphinganine ((2S,3R)-95). Reagents and...
Scheme 25: Synthesis of ceramide analogues (2S,3R)-96. Reagents and conditions: a) NaBH4, ZnCl2, MeOH, −78 °C,...
Scheme 26: Synthesis of orthogonally protected serinols, (S)-101 and (R)-102. Reagents and conditions: a) BnBr...
Scheme 27: Synthesis of N-acetyl-3-phenylserinol ((1R,2R)-105). Reagents and conditions: a) AcOH, CH2Cl2, refl...
Scheme 28: Synthesis of (S)-linezolid (S)-107. Reagents and conditions: a) LiAlH4, THF, 0 °C to reflux; b) Boc2...
Scheme 29: Synthesis of (2S,3S,4R)-2-aminooctadecane-1,3,4-triol (ᴅ-ribo-phytosphingosine) (2S,3S,4R)-110. Rea...
Scheme 30: Syntheses of ᴅ-phenylalanine (R)-116. Reagents and conditions: a) AcOH, CH2Cl2, reflux, 4 h; b) MsC...
Scheme 31: Synthesis of N-Boc-ᴅ-3,3-diphenylalanine ((R)-122). Reagents and conditions: a) PhMgBr, THF, −78 °C...
Scheme 32: Synthesis of ethyl N,N’-di-Boc-ʟ-2,3-diaminopropanoate ((S)-125). Reagents and conditions: a) NaN3,...
Scheme 33: Synthesis of the bicyclic amino acid (S)-(+)-127. Reagents and conditions: a) BF3·OEt2, THF, 60 °C,...
Scheme 34: Synthesis of lacosamide, (R)-2-acetamido-N-benzyl-3-methoxypropanamide (R)-130. Reagents and condit...
Scheme 35: Synthesis of N-Boc-norfuranomycin ((2S,2'R)-133). Reagents and conditions: a) H2C=CHCH2I, NaH, THF,...
Scheme 36: Synthesis of MeBmt (2S,3R,4R,6E)-139. Reagents and conditions: a) diisopropyl (S,S)-tartrate (E)-cr...
Scheme 37: Synthesis of (+)-polyoxamic acid (2S,3S,4S)-144. Reagents and conditions: a) AD-mix-α, MeSO2NH2, t-...
Scheme 38: Synthesis of the protected 3-hydroxy-ʟ-glutamic acid (2S,3R)-148. Reagents and conditions: a) LiHMD...
Scheme 39: Synthesis of (+)-isoserine (R)-152. Reagents and conditions: a) AcCl, MeCN, rt, 0.5 h then Na2CO3, ...
Scheme 40: Synthesis of (3R,4S)-N3-Boc-3,4-diaminopentanoic acid (3R,4S)-155. Reagents and conditions: a) Ph3P...
Scheme 41: Synthesis of methyl (2S,3S,4S)-4-(dimethylamino)-2,3-dihydroxy-5-methoxypentanoate (2S,3S,4S)-159. ...
Scheme 42: Syntheses of methyl (3S,4S) 4,5-di-N-Boc-amino-3-hydroxypentanoate ((3S,4S)-164), methyl (3S,4S)-4-N...
Scheme 43: Syntheses of (3R,5S)-5-(aminomethyl)-3-(4-methoxyphenyl)dihydrofuran-2(3H)-one ((3R,5S)-168). Reage...
Scheme 44: Syntheses of a series of imidazolin-2-one dipeptides 175–177 (for R' and R'' see text). Reagents an...
Scheme 45: Syntheses of (2S,3S)-N-Boc-3-hydroxy-2-hydroxymethylpyrrolidine ((2S,3S)-179). Reagents and conditi...
Scheme 46: Syntheses of enantiomers of 1,4-dideoxy-1,4-imino-ʟ- and -ᴅ-lyxitols (2S,3R,4S)-182 and (2R,3S,4R)-...
Scheme 47: Synthesis of 1,4-dideoxy-1,4-imino-ʟ-ribitol (2S,3S,4R)-182. Reagents and conditions: a) AcOH, CH2Cl...
Scheme 48: Syntheses of 1,4-dideoxy-1,4-imino-ᴅ-arabinitol (2R,3R,4R)-182 and 1,4-dideoxy-1,4-imino-ᴅ-xylitol ...
Scheme 49: Syntheses of natural 2,5-imino-2,5,6-trideoxy-ʟ-gulo-heptitol ((2S,3R,4R,5R)-184) and its C4 epimer...
Scheme 50: Syntheses of (−)-dihydropinidine ((2S,6R)-187a) (R = C3H7) and (2S,6R)-isosolenopsins (2S,6R)-187b ...
Scheme 51: Syntheses of (+)-deoxocassine ((2S,3S,6R)-190a, R = C12H25) and (+)-spectaline ((2S,3S,6R)-190b, R ...
Scheme 52: Synthesis of (−)-microgrewiapine A ((2S,3R,6S)-194a) and (+)-microcosamine A ((2S,3R,6S)-194b). Rea...
Scheme 53: Syntheses of ʟ-1-deoxynojirimycin ((2S,3S,4S,5R)-200), ʟ-1-deoxymannojirimycin ((2S,3S,4S,5S)-200) ...
Scheme 54: Syntheses of 1-deoxy-ᴅ-galacto-homonojirimycin (2R,3S,4R,5S)-211. Reagents and conditions: a) MeONH...
Scheme 55: Syntheses of 7a-epi-hyacinthacine A1 (1S,2R,3R,7aS)-220. Reagents and conditions: a) TfOTBDMS, 2,6-...
Scheme 56: Syntheses of 8-deoxyhyacinthacine A1 ((1S,2R,3R,7aR)-221). Reagents and conditions: a) H2, Pd/C, PT...
Scheme 57: Syntheses of (+)-lentiginosine ((1S,2S,8aS)-227). Reagents and conditions: a) (EtO)2P(O)CH2COOEt, L...
Scheme 58: Syntheses of 8-epi-swainsonine (1S,2R,8S,8aR)-231. Reagents and conditions: a) Ph3P=CHCOOMe, MeOH, ...
Scheme 59: Synthesis of a protected vinylpiperidine (2S,3R)-237, a key intermediate in the synthesis of (−)-sw...
Scheme 60: Synthesis of a modified carbapenem 245. Reagents and conditions: a) AcOEt, LiHMDS, THF, −78 °C, 1.5...
Beilstein J. Org. Chem. 2019, 15, 1612–1704, doi:10.3762/bjoc.15.165
Graphical Abstract
Figure 1: Various drugs having IP nucleus.
Figure 2: Participation percentage of various TMs for the syntheses of IPs.
Scheme 1: CuI–NaHSO4·SiO2-catalyzed synthesis of imidazo[1,2-a]pyridines.
Scheme 2: Experimental examination of reaction conditions.
Scheme 3: One-pot tandem reaction for the synthesis of 2-haloimidazopyridines.
Scheme 4: Mechanistic scheme for the synthesis of 2-haloimidazopyridine.
Scheme 5: Copper-MOF-catalyzed three-component reaction (3-CR) for imidazo[1,2-a]pyridines.
Scheme 6: Mechanism for copper-MOF-driven synthesis.
Scheme 7: Heterogeneous synthesis via titania-supported CuCl2.
Scheme 8: Mechanism involving oxidative C–H functionalization.
Scheme 9: Heterogeneous synthesis of IPs.
Scheme 10: One-pot regiospecific synthesis of imidazo[1,2-a]pyridines.
Scheme 11: Vinyl azide as an unprecedented substrate for imidazo[1,2-a]pyridines.
Scheme 12: Radical pathway.
Scheme 13: Cu(I)-catalyzed transannulation approach for imidazo[1,5-a]pyridines.
Scheme 14: Plausible radical pathway for the synthesis of imidazo[1,5-a]pyridines.
Scheme 15: A solvent-free domino reaction for imidazo[1,2-a]pyridines.
Scheme 16: Cu-NPs-mediated synthesis of imidazo[1,2-a]pyridines.
Scheme 17: CuI-catalyzed synthesis of isoxazolylimidazo[1,2-a]pyridines.
Scheme 18: Functionalization of 4-bromo derivative via Sonogashira coupling reaction.
Scheme 19: A plausible reaction pathway.
Scheme 20: Cu(I)-catalyzed intramolecular oxidative C–H amidation reaction.
Scheme 21: One-pot synthetic reaction for imidazo[1,2-a]pyridine.
Scheme 22: Plausible reaction mechanism.
Scheme 23: Cu(OAc)2-promoted synthesis of imidazo[1,2-a]pyridines.
Scheme 24: Mechanism for aminomethylation/cycloisomerization of propiolates with imines.
Scheme 25: Three-component synthesis of imidazo[1,2-a]pyridines.
Figure 3: Scope of pyridin-2(1H)-ones and acetophenones.
Scheme 26: CuO NPS-promoted A3 coupling reaction.
Scheme 27: Cu(II)-catalyzed C–N bond formation reaction.
Scheme 28: Mechanism involving Chan–Lam/Ullmann coupling.
Scheme 29: Synthesis of formyl-substituted imidazo[1,2-a]pyridines.
Scheme 30: A tandem sp3 C–H amination reaction.
Scheme 31: Probable mechanistic approach.
Scheme 32: Dual catalytic system for imidazo[1,2-a]pyridines.
Scheme 33: Tentative mechanism.
Scheme 34: CuO/CuAl2O4/ᴅ-glucose-promoted 3-CCR.
Scheme 35: A tandem CuOx/OMS-2-based synthetic strategy.
Figure 4: Biomimetic catalytic oxidation in the presence of electron-transfer mediators (ETMs).
Scheme 36: Control experiment.
Scheme 37: Copper-catalyzed C(sp3)–H aminatin reaction.
Scheme 38: Reaction of secondary amines.
Scheme 39: Probable mechanistic pathway.
Scheme 40: Coupling reaction of α-azidoketones.
Scheme 41: Probable pathway.
Scheme 42: Probable mechanism with free energy calculations.
Scheme 43: MCR for cyanated IP synthesis.
Scheme 44: Substrate scope for the reaction.
Scheme 45: Reaction mechanism.
Scheme 46: Probable mechanistic pathway for Cu/ZnAl2O4-catalyzed reaction.
Scheme 47: Copper-catalyzed double oxidative C–H amination reaction.
Scheme 48: Application towards different coupling reactions.
Scheme 49: Reaction mechanism.
Scheme 50: Condensation–cyclization approach for the synthesis of 1,3-diarylated imidazo[1,5-a]pyridines.
Scheme 51: Optimized reaction conditions.
Scheme 52: One-pot 2-CR.
Scheme 53: One-pot 3-CR without the isolation of chalcone.
Scheme 54: Copper–Pybox-catalyzed cyclization reaction.
Scheme 55: Mechanistic pathway catalyzed by Cu–Pybox complex.
Scheme 56: Cu(II)-promoted C(sp3)-H amination reaction.
Scheme 57: Wider substrate applicability for the reaction.
Scheme 58: Plausible reaction mechanism.
Scheme 59: CuI assisted C–N cross-coupling reaction.
Scheme 60: Probable reaction mechanism involving sp3 C–H amination.
Scheme 61: One-pot MCR-catalyzed by CoFe2O4/CNT-Cu.
Scheme 62: Mechanistic pathway.
Scheme 63: Synthetic scheme for 3-nitroimidazo[1,2-a]pyridines.
Scheme 64: Plausible mechanism for CuBr-catalyzed reaction.
Scheme 65: Regioselective synthesis of halo-substituted imidazo[1,2-a]pyridines.
Scheme 66: Synthesis of 2-phenylimidazo[1,2-a]pyridines.
Scheme 67: Synthesis of diarylated compounds.
Scheme 68: CuBr2-mediated one-pot two-component oxidative coupling reaction.
Scheme 69: Decarboxylative cyclization route to synthesize 1,3-diarylimidazo[1,5-a]pyridines.
Scheme 70: Mechanistic pathway.
Scheme 71: C–H functionalization reaction of enamines to produce diversified heterocycles.
Scheme 72: A plausible mechanism.
Scheme 73: CuI-promoted aerobic oxidative cyclization reaction of ketoxime acetates and pyridines.
Scheme 74: CuI-catalyzed pathway for the formation of imidazo[1,2-a]pyridine.
Scheme 75: Mechanistic pathway.
Scheme 76: Mechanistic rationale for the synthesis of products.
Scheme 77: Copper-catalyzed synthesis of vinyloxy-IP.
Scheme 78: Regioselective product formation with propiolates.
Scheme 79: Proposed mechanism for vinyloxy-IP formation.
Scheme 80: Regioselective synthesis of 3-hetero-substituted imidazo[1,2-a]pyridines with different reaction su...
Scheme 81: Mechanistic pathway.
Scheme 82: CuI-mediated synthesis of 3-formylimidazo[1,2-a]pyridines.
Scheme 83: Radical pathway for 3-formylated IP synthesis.
Scheme 84: Pd-catalyzed urea-cyclization reaction for IPs.
Scheme 85: Pd-catalyzed one-pot-tandem amination and intramolecular amidation reaction.
Figure 5: Scope of aniline nucleophiles.
Scheme 86: Pd–Cu-catalyzed Sonogashira coupling reaction.
Scheme 87: One-pot amide coupling reaction for the synthesis of imidazo[4,5-b]pyridines.
Scheme 88: Urea cyclization reaction for the synthesis of two series of pyridines.
Scheme 89: Amidation reaction for the synthesis of imidazo[4,5-b]pyridines.
Figure 6: Amide scope.
Scheme 90: Pd NPs-catalyzed 3-component reaction for the synthesis of 2,3-diarylated IPs.
Scheme 91: Plausible mechanistic pathway for Pd NPs-catalyzed MCR.
Scheme 92: Synthesis of chromenoannulated imidazo[1,2-a]pyridines.
Scheme 93: Mechanism for the synthesis of chromeno-annulated IPs.
Scheme 94: Zinc oxide NRs-catalyzed synthesis of imidazo[1,2-a]azines/diazines.
Scheme 95: Zinc oxide-catalyzed isocyanide based GBB reaction.
Scheme 96: Reaction pathway for ZnO-catalyzed GBB reaction.
Scheme 97: Mechanistic pathway.
Scheme 98: ZnO NRs-catalyzed MCR for the synthesis of imidazo[1,2-a]azines.
Scheme 99: Ugi type GBB three-component reaction.
Scheme 100: Magnetic NPs-catalyzed synthesis of imidazo[1,2-a]pyridines.
Scheme 101: Regioselective synthesis of 2-alkoxyimidazo[1,2-a]pyridines catalyzed by Fe-SBA-15.
Scheme 102: Plausible mechanistic pathway for the synthesis of 2-alkoxyimidazopyridine.
Scheme 103: Iron-catalyzed synthetic approach.
Scheme 104: Iron-catalyzed aminooxygenation reaction.
Scheme 105: Mechanistic pathway.
Scheme 106: Rh(III)-catalyzed double C–H activation of 2-substituted imidazoles and alkynes.
Scheme 107: Plausible reaction mechanism.
Scheme 108: Rh(III)-catalyzed non-aromatic C(sp2)–H bond activation–functionalization for the synthesis of imid...
Scheme 109: Reactivity and selectivity of different substrates.
Scheme 110: Rh-catalyzed direct C–H alkynylation by Li et al.
Scheme 111: Suggested radical mechanism.
Scheme 112: Scandium(III)triflate-catalyzed one-pot reaction and its mechanism for the synthesis of benzimidazo...
Scheme 113: RuCl3-assisted Ugi-type Groebke–Blackburn condensation reaction.
Scheme 114: C-3 aroylation via Ru-catalyzed two-component reaction.
Scheme 115: Regioselective synthetic mechanism.
Scheme 116: La(III)-catalyzed one-pot GBB reaction.
Scheme 117: Mechanistic approach for the synthesis of imidazo[1,2-a]pyridines.
Scheme 118: Synthesis of imidazo[1,2-a]pyridine using LaMnO3 NPs under neat conditions.
Scheme 119: Mechanistic approach.
Scheme 120: One-pot 3-CR for regioselective synthesis of 2-alkoxy-3-arylimidazo[1,2-a]pyridines.
Scheme 121: Formation of two possible products under optimization of the catalysts.
Scheme 122: Mechanistic strategy for NiFe2O4-catalyzed reaction.
Scheme 123: Two-component reaction for synthesizing imidazodipyridiniums.
Scheme 124: Mechanistic scheme for the synthesis of imidazodipyridiniums.
Scheme 125: CuI-catalyzed arylation of imidazo[1,2-a]pyridines.
Scheme 126: Mechanism for arylation reaction.
Scheme 127: Cupric acetate-catalyzed double carbonylation approach.
Scheme 128: Radical mechanism for double carbonylation of IP.
Scheme 129: C–S bond formation reaction catalyzed by cupric acetate.
Scheme 130: Cupric acetate-catalyzed C-3 formylation approach.
Scheme 131: Control experiments for signifying the role of DMSO and oxygen.
Scheme 132: Mechanism pathway.
Scheme 133: Copper bromide-catalyzed CDC reaction.
Scheme 134: Extension of the substrate scope.
Scheme 135: Plausible radical pathway.
Scheme 136: Transannulation reaction for the synthesis of imidazo[1,5-a]pyridines.
Scheme 137: Plausible reaction pathway for denitrogenative transannulation.
Scheme 138: Cupric acetate-catalyzed C-3 carbonylation reaction.
Scheme 139: Plausible mechanism for regioselective C-3 carbonylation.
Scheme 140: Alkynylation reaction at C-2 of 3H-imidazo[4,5-b]pyridines.
Scheme 141: Two-way mechanism for C-2 alkynylation of 3H-imidazo[4,5-b]pyridines.
Scheme 142: Palladium-catalyzed SCCR approach.
Scheme 143: Palladium-catalyzed Suzuki coupling reaction.
Scheme 144: Reaction mechanism.
Scheme 145: A phosphine free palladium-catalyzed synthesis of C-3 arylated imidazopyridines.
Scheme 146: Palladium-mediated Buchwald–Hartwig cross-coupling reaction.
Figure 7: Structure of the ligands optimized.
Scheme 147: Palladium acetate-catalyzed direct arylation of imidazo[1,2-a]pyridines.
Scheme 148: Palladium acetate-catalyzed mechanistic pathway.
Scheme 149: Palladium acetate-catalyzed regioselective arylation reported by Liu and Zhan.
Scheme 150: Mechanism for selective C-3 arylation of IP.
Scheme 151: Pd(II)-catalyzed alkenylation reaction with styrenes.
Scheme 152: Pd(II)-catalyzed alkenylation reaction with acrylates.
Scheme 153: A two way mechanism.
Scheme 154: Double C–H activation reaction catalyzed by Pd(OAc)2.
Scheme 155: Probable mechanism.
Scheme 156: Palladium-catalyzed decarboxylative coupling.
Scheme 157: Mechanistic cycle for decarboxylative arylation reaction.
Scheme 158: Ligand-free approach for arylation of imidazo[1,2-a]pyridine-3-carboxylic acids.
Scheme 159: Mechanism for ligandless arylation reaction.
Scheme 160: NHC-Pd(II) complex assisted arylation reaction.
Scheme 161: C-3 arylation of imidazo[1,2-a]pyridines with aryl bromides catalyzed by Pd(OAc)2.
Scheme 162: Pd(II)-catalyzed C-3 arylations with aryl tosylates and mesylates.
Scheme 163: CDC reaction for the synthesis of imidazo[1,2-a]pyridines.
Scheme 164: Plausible reaction mechanism for Pd(OAc)2-catalyzed synthesis of imidazo[1,2-a]pyridines.
Scheme 165: Pd-catalyzed C–H amination reaction.
Scheme 166: Mechanism for C–H amination reaction.
Scheme 167: One-pot synthesis for 3,6-di- or 2,3,6-tri(hetero)arylimidazo[1,2-a]pyridines.
Scheme 168: C–H/C–H cross-coupling reaction of IPs and azoles catalyzed by Pd(II).
Scheme 169: Mechanistic cycle.
Scheme 170: Rh-catalyzed C–H arylation reaction.
Scheme 171: Mechanistic pathway for C–H arylation of imidazo[1,2-a]pyridine.
Scheme 172: Rh(III)-catalyzed double C–H activation of 2-phenylimidazo[1,2-a]pyridines and alkynes.
Scheme 173: Rh(III)-catalyzed mechanistic pathway.
Scheme 174: Rh(III)-mediated oxidative coupling reaction.
Scheme 175: Reactions showing functionalization of the product obtained by the group of Kotla.
Scheme 176: Mechanism for Rh(III)-catalyzed oxidative coupling reaction.
Scheme 177: Rh(III)-catalyzed C–H activation reaction.
Scheme 178: Mechanistic cycle.
Scheme 179: Annulation reactions of 2-arylimidazo[1,2-a]pyridines and alkynes.
Scheme 180: Two-way reaction mechanism for annulations reaction.
Scheme 181: [RuCl2(p-cymene)]2-catalyzed C–C bond formation reaction.
Scheme 182: Reported reaction mechanism.
Scheme 183: Fe(III) catalyzed C-3 formylation approach.
Scheme 184: SET mechanism-catalyzed by Fe(III).
Scheme 185: Ni(dpp)Cl2-catalyzed KTC coupling.
Scheme 186: Pd-catalyzed SM coupling.
Scheme 187: Vanadium-catalyzed coupling of IP and NMO.
Scheme 188: Mechanistic cycle.
Scheme 189: Selective C3/C5–H bond functionalizations by mono and bimetallic systems.
Scheme 190: rGO-Ni@Pd-catalyzed C–H bond arylation of imidazo[1,2-a]pyridine.
Scheme 191: Mechanistic pathway for heterogeneously catalyzed arylation reaction.
Scheme 192: Zinc triflate-catalyzed coupling reaction of substituted propargyl alcohols.
Beilstein J. Org. Chem. 2019, 15, 1355–1359, doi:10.3762/bjoc.15.135
Graphical Abstract
Figure 1: Structure of boronic acid analogues (for clarity, sugar numbering has been conserved into the analo...
Figure 2: Structures of boron analogues.
Figure 3: Synthetic strategy.
Scheme 1: Synthesis of 2-deoxy analogue 8.
Figure 4: Postulated transition states for the hydroboration reaction.
Scheme 2: Synthesis of 2,3-dideoxy analogue 11.
Beilstein J. Org. Chem. 2019, 15, 1331–1338, doi:10.3762/bjoc.15.132
Graphical Abstract
Figure 1: Interactions of a pair of dipolar rotors in different orientations. The axes of the rotors are para...
Figure 2: Structures of molecular dipolar rotors/linker molecules 1–5.
Scheme 1: General synthetic strategy to prepare the dipolar rotors 1–5.
Scheme 2: Synthesis of 3,3'-(2,3-difluoro-1,4-phenylene)dipropiolic acid (1) starting with diiodination of 1,...
Scheme 3: Synthesis of 3,3'-(5,6-Difluoro-2,1,3-benzothiadiazol-4,7-diyl)dipropiolic acid (2) and 3,3'-(5,6-D...
Scheme 4: Synthesis of 3,3'-(5,6-dicyano-1,3-benzodioxole-4,7-diyl)dipropiolic acid (4) and 3,3'-(6,7-dicyano...
Beilstein J. Org. Chem. 2019, 15, 1236–1256, doi:10.3762/bjoc.15.121
Graphical Abstract
Figure 1: Structures of natural steroids of A) animal and B) plant origin.
Scheme 1: Synthesis of a steroidal β-lactam by Ugi reaction of a cholanic aldehyde [14].
Scheme 2: Synthetic route to steroidal 2,5-diketopiperazines based on a diastereoselective Ugi-4CR with an an...
Scheme 3: Multicomponent synthesis of a heterocycle–steroid hybrid using a ketosteroid as carbonyl component [18]....
Scheme 4: Synthesis of peptidomimetic–steroid hybrids using the Ugi-4CR with spirostanic amines and carboxyli...
Scheme 5: Synthesis of azasteroids using the Ugi-4CR with androstanic and pregnanic carboxylic acids [22].
Figure 2: Ugi-4CR-derived library of androstanic azasteroids with diverse substitution patterns at the phenyl...
Scheme 6: Synthesis of 4-azacholestanes by an intramolecular Ugi-4C-3R [26].
Scheme 7: Synthesis of amino acid–steroid hybrid by multiple Ugi-4CR using steroidal isocyanides [29].
Scheme 8: Synthesis of ecdysteroid derivatives by Ugi-4CR using a steroidal isocyanide [30].
Scheme 9: Stereoselective multicomponent synthesis of a steroid–tetrahydropyridine hybrid using a chiral bifu...
Scheme 10: Pd(II)-catalyzed three-component reaction with an alkynyl seco-cholestane [34].
Scheme 11: Multicomponent synthesis of steroid–thiazole hybrids from a steroidal ketone [36].
Scheme 12: Synthesis of cholanic pseudo-peptide derivatives by novel MCRs based on the reactivity of ynamide [37,38].
Scheme 13: Synthesis of steroid-fused pyrimidines and pyrimidones using the Biginelli-3CR [39,42,43].
Scheme 14: Synthesis of steroidal pyridopyrimidines by a reaction sequence comprising a 4CR followed by a post...
Scheme 15: Synthesis of steroid-fused pyrimidines by MCR of 2-hydroxymethylene-3-ketosteroids [46].
Scheme 16: Synthesis of steroid-fused naphthoquinolines by the Kozlov–Wang MCR using ketosteroids [50,51].
Scheme 17: Conjugation of steroids to carbohydrates and peptides by the Ugi-4CR [62,63].
Scheme 18: Solid-phase multicomponent conjugation of peptides to steroids by the Ugi-4CR [64].
Scheme 19: Solid-phase multicomponent conjugation of peptides to steroids by the Petasis-3CR [68].
Scheme 20: Synthesis of steroidal macrobicycles (cages) by multiple multicomponent macrocyclizations based on ...
Scheme 21: One-pot synthesis of steroidal cages by double Ugi-4CR-based macrocyclizations [76].
Beilstein J. Org. Chem. 2019, 15, 1020–1031, doi:10.3762/bjoc.15.100
Graphical Abstract
Figure 1: Graphical summary of chemically contiguous opioid vaccine approach. A) Illustration of chemically c...
Figure 2: The chemically contiguous heroin–fentanyl haptens designed in this study. Grouping was based on the...
Figure 3: Heroin intermediates used to synthesize HF-1 through HF-9.
Scheme 1: General outline of HF-1, HF-2, HF-3, HF-7 synthesis from fentanyl intermediate 5 and heroin interme...
Scheme 2: Synthesis of fentanyl intermediate 5. Reaction conditions: a) phthalic anhydride, AcOH, reflux, 81%...
Scheme 3: General outline of HF-5, HF-8, HF-9 synthesis from fentanyl intermediates 28 and 46, and heroin int...
Scheme 4: Parallel synthesis of fentanyl domains 25 and 34, for HF-4 and HF-6, respectively.
Scheme 5: General strategy and coupling partners for the chemically contiguous series. aGeneral conditions fo...
Figure 4: Vaccination, titer assessment, and bleed schedule.
Figure 5: Summary of behavioral data for most promising chemically contiguous vaccine HF-7, compared to singu...
Figure 6: Summary of behavioral data for phenethyl-linked haptens HF-4 and HF-6. Bars represent mean ± SEM.
Figure 7: Correlation plots of dual hapten vaccines comparing week 5 and 8 ELISA midpoint titers to ED50 valu...
Beilstein J. Org. Chem. 2019, 15, 906–930, doi:10.3762/bjoc.15.88
Graphical Abstract
Scheme 1: Comparison between a normal sequential reaction and an MCR.
Scheme 2: Synthesis of tetrazoles and hydantoinimide derivatives by consecutive Ugi reactions [17].
Scheme 3: Synthesis of tetrazole-ketopiperazines by two consecutive Ugi reactions [19].
Scheme 4: Synthesis of acylhydrazino bis(1,5-disubstituted tetrazoles) through two hydrazine-Ugi-azide reacti...
Scheme 5: Synthesis of substituted α-aminomethyltetrazoles through two consecutive Ugi reactions (U-4CR and U...
Scheme 6: Synthesis of tetrazole peptidomimetics by direct use of amino acids in two consecutive Ugi reaction...
Scheme 7: One-pot 8CR based on 3 sequential IMCRs [25].
Scheme 8: Combination of IMCRs for the synthesis of substituted 2H-imidazolines [25].
Scheme 9: 6CR involving a tandem combination of Groebke–Blackburn–Bienaymé and Ugi reaction for the synthesis...
Scheme 10: 5CR involving a tandem combination of Groebke–Blackburn–Bienaymé and Passerini reaction for the syn...
Scheme 11: Synthesis of tubugis via three consecutive IMCRs [27].
Scheme 12: Synthesis of telaprevir through consecutive IMCRs [28].
Scheme 13: Another synthesis of telaprevir through consecutive IMCRs [29].
Scheme 14: a) Synthetic sequence for accessing diverse macrocycles containing the tetrazole nucleus by the uni...
Scheme 15: a) Synthetic sequence for the tetrazolic macrocyclic depsipeptides using a combination of two IMCRs...
Scheme 16: Synthesis of cyclic pentapeptoids by consecutive Ugi reactions [32].
Scheme 17: Synthesis of a cyclic pentapeptoid by consecutive Ugi reactions [32].
Scheme 18: MW-mediated synthesis of a cyclopeptoid by consecutive Ugi reactions [33].
Scheme 19: Synthesis of six cyclic pentadepsipeptoids via consecutive isocyanide-based IMCRs [34].
Scheme 20: Microwave-mediated synthesis of a cyclic heptapeptoid through four consecutive IMCRs [35].
Scheme 21: Macrocyclization of bifunctional building blocks containing diacid/diisonitrile and diamine/diisoni...
Scheme 22: Synthesis of steroid-biaryl ether hybrid macrocycles by MiBs [38].
Scheme 23: Synthesis of biaryl ether-containing macrocycles by MiBs [39].
Scheme 24: Synthesis of natural product-inspired biaryl ether-cyclopeptoid macrocycles [40].
Scheme 25: Synthesis of cholane-based hybrid macrolactams by MiBs [41].
Scheme 26: Synthesis of macrocyclic oligoimine-based DCL using the Ugi-4CR-based quenching approach [42].
Scheme 27: Dye-modified and photoswitchable macrocycles by MiBs [43].
Scheme 28: Synthesis of nonsymmetric cryptands by two sequential double Ugi-4CR-based macrocyclizations [44].
Scheme 29: Synthesis of steroid–aryl hybrid cages by sequential 2- and 3-fold Ugi-4CR-based macrocyclizations [46]....
Scheme 30: Ugi-MiBs approach towards natural product-like macrocycles [47].
Scheme 31: a) Bidirectional macrocyclization of peptides by double Ugi reaction. b) Ugi-4CR for the generation...
Scheme 32: MiBs based on the Passerini-3CR for the synthesis of macrolactones [49].
Scheme 33: Template-driven approach for the synthesis of macrotricycles 170 [50].
Beilstein J. Org. Chem. 2019, 15, 761–768, doi:10.3762/bjoc.15.72
Graphical Abstract
Figure 1: Structure of biaryl bicyclic peptides 1–3.
Scheme 1: Retrosynthetic analysis for the biaryl bicyclic peptide 1.
Scheme 2: Synthesis of the biaryl bicyclic peptide 1 incorporating a Phe-Phe linkage. Reagents and conditions...
Scheme 3: Synthesis of the biaryl bicyclic peptide 2 incorporating a Phe-Tyr linkage. Reagents and conditions...
Scheme 4: Synthesis of the biaryl bicyclic peptide 3 incorporating a Tyr-Tyr linkage. Reagents and conditions...
Beilstein J. Org. Chem. 2019, 15, 679–684, doi:10.3762/bjoc.15.62
Graphical Abstract
Scheme 1: Preparation of hydroxyalkynyl substrates from 1-phenyl-1H-pyrazol-3-ol (1).
Scheme 2: Cyclization of hydroxyalkynyl substrates to 2,5-disubstituted 2H-furo[2,3-c]pyrazoles.
Figure 1: a) ORTEP diagram of the asymmetric unit consisting of two independent molecules 4d(A) and 4d(B); b)...
Beilstein J. Org. Chem. 2019, 15, 431–436, doi:10.3762/bjoc.15.37
Graphical Abstract
Figure 1: Structure of the synthesized pentasaccharide corresponding to the repeating unit of the biofilms pr...
Scheme 1: Reagents and conditions: (a) i: Bu2SnO, CH3OH, 80 °C, 2 h; ii: allyl bromide, CsF, DMF, 65 °C, 6 h;...
Scheme 2: Reagents and conditions: (a) Benzoyl chloride, pyridine, 0 °C, 3 h, 75%; (b) Tf2O, BSP, TTBP, CH2Cl2...
Scheme 3: Reagents and conditions: (a) TMSOTf, CH2Cl2, −10 °C, 30 min, 45%; (b) NIS, TMSOTf, MS 4 Å, CH2Cl2, ...
Scheme 4: Reagents and conditions: (a) NIS, TMSOTf, MS 4 Å, CH2Cl2, −50 °C, 2 h, 70%; (b) benzyl bromide, NaO...
Beilstein J. Org. Chem. 2019, 15, 388–400, doi:10.3762/bjoc.15.35
Graphical Abstract
Figure 1: Structures of some bioactive 4-oxoquinoline-3-carboxamide derivatives 1–4 with different bioactive ...
Figure 2: Structural modifications on the 4-oxo-1,4-dihydroquinoline-3-carboxamide scaffold.
Scheme 1: Synthetic route for the preparation of 1-ethyl-4-oxoquinoline-3-carboxamide 7.
Scheme 2: Reaction steps and main transition state leading to compound 7.
Figure 3: Same scale partial 1H NMR spectra of compounds 5 and 7 (DMSO-d6, 500 MHz).
Figure 4: 1H,1H-COSY spectrum of derivative 7 (DMSO-d6, 500 MHz).
Figure 5: Partial HMBC spectrum of derivative 7 (DMSO-d6, 500 MHz).
Figure 6: Asymmetric unit of product 7.
Scheme 3: Deprotonation of 5 forming 8a and 8b, followed by reaction with bromoethane leading to products 7 a...
Scheme 4: Acid–base equilibria considered for the data displayed in Table 2.
Scheme 5: Charge dispersion due to resonance effects for both deprotonated species.
Beilstein J. Org. Chem. 2019, 15, 371–377, doi:10.3762/bjoc.15.33
Graphical Abstract
Figure 1: Exemplar C3-symmetric peptide scaffolds reported in the literature.
Scheme 1: Preparation of compound 7 from L-serine (3).
Scheme 2: Preparation of the trimerized product 9.
Scheme 3: Synthesis of compound 11 via Negishi cross-coupling reaction.
Scheme 4: Synthesis of C3-symmetric trimers 12, 13 and 14.
Beilstein J. Org. Chem. 2018, 14, 2822–2828, doi:10.3762/bjoc.14.260
Graphical Abstract
Figure 1: Structures of hamamelitannin (1), lead compound 2 and target compounds 3.
Scheme 1: Proposed strategy for the synthesis of the target analogues.
Scheme 2: Synthesis of fragment 9. Reagents and conditions: a) phthalimide, Pd2(allyl)2Cl2, ligand 15, Na2CO3...
Scheme 3: Synthesis of fragment 10. Reagents and conditions: a) TBSCl, NaH, THF, rt; b) phthalimide, PPh3, DE...
Scheme 4: Coupling of 9 and 10 and attempted ring-closing metathesis. Reagents and conditions: a) PPh3, DEAD,...
Scheme 5: Synthesis of alternative eastern fragment 23. Reagents and conditions: a) TBSCl, imidazole, CH2Cl2,...
Scheme 6: Synthesis of 4. Reagents and conditions: a) PPh3, DEAD, THF, 0 °C to rt; b) Grubbs–Hoveyda II (5 mo...
Scheme 7: Late stage functionalization of the pyrrolidine nitrogen. Reagents and conditions: A) (masked) alde...
Figure 2: Molecular X-ray structure of 3a, showing thermal displacement ellipsoids at the 50% probability lev...
Beilstein J. Org. Chem. 2018, 14, 2665–2679, doi:10.3762/bjoc.14.244
Graphical Abstract
Figure 1: (a) Structure of universal nova tag resin, (b) structure of H-L-Cys(Trt)-2-ClTrt resin.
Figure 2: (a) PSMA targeted DUPA rhodamine B chelating conjugate 13. (b) Folate receptor targeted pteroate rh...
Scheme 1: Synthesis of PSMA tris(tert-butoxy) protected DUPA ligand 4. Reagents and conditions: (a) Triphosge...
Scheme 2: Attempted synthesis of PSMA targeted DUPA rhodamine B chelating conjugate 13 using Fmoc-Lys(Mtt/Mmt...
Scheme 3: Synthesis of PSMA targeting DUPA rhodamine B chelating conjugate 13. Reagents and conditions: (a) F...
Scheme 4: Synthesis of folate receptor targeting pteroate rhodamine B chelating conjugate 17. Reagents and co...
Figure 3: (i) and (ix) DIC image of LNCaP cells (PSMA+); (ii) binding and internalization of DUPA-rhodamine B...
Beilstein J. Org. Chem. 2018, 14, 2618–2626, doi:10.3762/bjoc.14.240
Graphical Abstract
Scheme 1: C–H/C–Li cross-coupling reactions of 2H-imidazole 1-oxides 1a–d and carboranyl lithium 2. The react...
Figure 1: The 1H NMR spectra of 1-(5-(4-bromophenyl)-2-ethyl-2-methyl-2H-imidazol-4-yl)-1,2-dicarba-closo-dod...
Figure 2: Fragment of the 2D 1H–13C{1H} HSQC (a) and HMBC (b) spectra of imidazolyl carborane 5d in CDCl3 at ...
Figure 3: Molecular structure of 5d. Selected bond distances (Å) and angles (deg) for molecule 1: C(3)–C(14),...
Beilstein J. Org. Chem. 2018, 14, 2537–2544, doi:10.3762/bjoc.14.230
Graphical Abstract
Figure 1: Various alkaloids containing propellane frame work.
Scheme 1: Synthesis of the star-shaped norbornene derivative 11 via trimerization.
Figure 2: Selected list of ruthenium-based catalysts used for ROM.
Scheme 2: Synthesis of the C3-symmetric molecule 15 bearing propellane moieties via trimerization and RCM.
Scheme 3: Synthesis of C3-symmetric molecule 21 bearing propellane moieties via trimerization and RCM.
Beilstein J. Org. Chem. 2018, 14, 2510–2519, doi:10.3762/bjoc.14.227
Graphical Abstract
Figure 1: N-Aryl-3,4-dihydroquinazolines 1.
Scheme 1: Synthetic pathway leading to N-aryl-3,4-dihydroquinazolines 1.
Scheme 2: Synthesis of compounds 2.
Figure 2: Reaction intermediate in the synthesis of compound 2a.
Scheme 3: Addition–elimination mechanism for the heterocyclization.
Scheme 4: Proposed mechanism involving an intermediate nitrilium ion.
Beilstein J. Org. Chem. 2018, 14, 2482–2487, doi:10.3762/bjoc.14.224
Graphical Abstract
Figure 1: Structures of leopolic acid A and compound 1.
Scheme 1: Synthesis of 3-decyltetramic intermediate 13. Reagent and conditions: a) TEA, THF, 0 °C to rt, 2.5 ...
Scheme 2: Synthesis of dipeptide L-Phe-L-Val intermediate 20. Reagents and conditions: a) PTSA·H2O, benzyl al...
Scheme 3: Synthesis of compound 1. Reagents and conditions: a) n-BuLi, THF, −60 °C, 220 min, 60%; b) H2, Pd/C...
Beilstein J. Org. Chem. 2018, 14, 2035–2064, doi:10.3762/bjoc.14.179
Graphical Abstract
Figure 1: Depiction of the energy levels of a typical organic molecule and the photophysical processes it can...
Figure 2: General catalytic cycle of a photocatalyst in a photoredox organocatalysed reaction. [cat] – photoc...
Figure 3: Structures and names of the most common photocatalysts encountered in the reviewed literature.
Figure 4: General example of a reductive quenching catalytic cycle. [cat] – photocatalyst, [cat]* – photocata...
Figure 5: General example of an oxidative quenching catalytic cycle. [cat] – photocatalyst, [cat]* – photocat...
Scheme 1: Oxidative coupling of aldehydes and amines to amides using acridinium salt photocatalysis.
Figure 6: Biologically active molecules containing a benzamide linkage.
Scheme 2: The photocatalytic reduction of amino acids to produce the corresponding free or protected amines.
Scheme 3: The organocatalysed photoredox base-mediated oxidation of thiols to disulfides.
Scheme 4: C-Terminal modification of peptides and proteins using organophotoredox catalysis.
Scheme 5: The reduction and aryl coupling of aryl halides using a doubly excited photocatalyst (PDI).
Figure 7: Mechanism for the coupling of aryl halides using PDI, which is excited sequentially by two photons.
Scheme 6: The arylation of five-membered heteroarenes using arenediazonium salts under organophotoredox condi...
Scheme 7: The C–H (hetero)arylation of five-membered heterocycles under Eosin Y photocatalysis.
Scheme 8: The C–H sulfurisation of imidazoheterocycles using Eosin B-catalyzed photochemical methods.
Scheme 9: The introduction of the thiocyanate group using Eosin Y photocatalysis.
Scheme 10: Sulfonamidation of pyrroles using oxygen as the terminal oxidant.
Scheme 11: DDQ-catalysed C–H amination of arenes and heteroarenes.
Scheme 12: Photoredox-promoted radical Michael addition reactions of allylic or benzylic carbons.
Figure 8: Proposed mechanistic rationale for the observed chemoselectivities.
Scheme 13: The photocatalytic manipulation of C–H bonds adjacent to amine groups.
Scheme 14: The perylene-catalysed organophotoredox tandem difluoromethylation–acetamidation of styrene-type al...
Figure 9: Examples of biologically active molecules containing highly functionalised five membered heterocycl...
Scheme 15: The [3 + 2]-cycloaddition leading to the formation of pyrroles, through the reaction of 2H-azirines...
Figure 10: Proposed intermediate that determines the regioselectivity of the reaction.
Figure 11: Comparison of possible pathways of reaction and various intermediates involved.
Scheme 16: The acridinium salt-catalysed formation of oxazoles from aldehydes and 2H-azirines.
Scheme 17: The synthesis of oxazolines and thiazolines from amides and thioamides using organocatalysed photor...
Figure 12: Biologically active molecules on the market containing 1,3,4-oxadiazole moieties.
Scheme 18: The synthesis of 1,3,4-oxadiazoles from aldehyde semicarbazones using Eosin Y organophotocatalysis.
Scheme 19: The dimerization of primary thioamides to 1,2,4-thiadiazoles catalysed by the presence of Eosin Y a...
Scheme 20: The radical cycloaddition of o-methylthioarenediazonium salts and substituted alkynes towards the f...
Scheme 21: The dehydrogenative cascade reaction for the synthesis of 5,6-benzofused heterocyclic systems.
Figure 13: Trifluoromethylated version of compounds which have known biological activities.
Scheme 22: Eosin Y-catalysed photoredox formation of 3-substituted benzimidazoles.
Scheme 23: Oxidation of dihydropyrimidines by atmospheric oxygen using photoredox catalysis.
Scheme 24: Photoredox-organocatalysed transformation of 2-substituted phenolic imines to benzoxazoles.
Scheme 25: Visible light-driven oxidative annulation of arylamidines.
Scheme 26: Methylene blue-photocatalysed direct C–H trifluoromethylation of heterocycles.
Scheme 27: Photoredox hydrotrifluoromethylation of terminal alkenes and alkynes.
Scheme 28: Trifluoromethylation and perfluoroalkylation of aromatics and heteroaromatics.
Scheme 29: The cooperative asymmetric and photoredox catalysis towards the functionalisation of α-amino sp3 C–...
Scheme 30: Organophotoredox-catalysed direct C–H amidation of aromatics.
Scheme 31: Direct C–H alkylation of heterocycles using BF3K salts. CFL – compact fluorescent lamp.
Figure 14: The modification of camptothecin, demonstrating the use of the Molander protocol in LSF.
Scheme 32: Direct C–H amination of aromatics using acridinium salts.
Scheme 33: Photoredox-catalysed nucleophilic aromatic substitution of nucleophiles onto methoxybenzene derivat...
Scheme 34: The direct C–H cyanation of aromatics with a focus on its use for LSF.
Beilstein J. Org. Chem. 2018, 14, 1743–1749, doi:10.3762/bjoc.14.148
Graphical Abstract
Scheme 1: Possible intermediates of the interaction of alkynyl compounds with Ar–Cu(III) species.
Scheme 2: Two possible reaction routes for the oxazoline formation explored by computations. The schemes indi...
Scheme 3: Free energy profiles for the possible reaction routes. The final energy state (−50.5 kcal/mol) is n...
Beilstein J. Org. Chem. 2018, 14, 1459–1481, doi:10.3762/bjoc.14.124
Graphical Abstract
Figure 1: Molecular structure of neutral platinum(II) complex 1 bearing four monodentate ligands; cy = cycloh...
Figure 2: Chemical structure of the dinuclear Pt complexes 2a–b and 3 [20].
Figure 3: Molecular structure of platinum(II) complexes bearing isoquinolinylpyrazolates; dip = 2,6-diisoprop...
Figure 4: Selected neutral platinum(II) complexes featuring dianionic biazolate and neutral bipyridines [27].
Figure 5: Selected neutral platinum(II) complexes from bipyrazolate and carbene-based chelates [34,35].
Figure 6: Cyclometalated thiazol-2-ylidene platinum(II) complexes with different acetylacetonate ligands [37].
Figure 7: Neutral platinum(II) complexes 13–15 bearing azolate ligands [13].
Figure 8: Chemical structure of neutral platinum(II) complexes 16–18 bearing azine-pyrazolato bidentate ligan...
Figure 9: Molecular structure of carbene-containing cyclometallated alkynylplatinum(II) complexes 19–21 [41].
Figure 10: Chemical structure of platinum(II) complexes 22a–d bearing asymmetric C^N^N tridentate ligands [53].
Figure 11: Chemical structure of platinum(II) complexes 23 bearing bis-cyclometalating 2,6-dipyridylbenzene ty...
Figure 12: Molecular structure of dendritic carbazole-containing alkynyl-platinum(II) complexes 24a–d [62].
Figure 13: Molecular structure of bipolar alkynyl-platinum(II) complexes 25 bearing carbazole and electron-acc...
Figure 14: Molecular structures of neutral platinum(II) complexes comprising donor-acceptor alkynyls (26) or e...
Figure 15: Chemical structure of the asymmetric Pt(II) derivatives 28 bearing triazole and tetrazole moieties ...
Figure 16: Molecular structure of the tetradentate platinum complexes 29–32 bearing N^C^C^N and C^C^C^N ligand...
Figure 17: Chemical structure of the tetradentate Pt complexes 33–38 based on N^C^C^N-type of ligands [80-84].
Figure 18: Chemical structure of the macrocyclic tetradentate platinum complexes reported by Wang and co-worke...
Figure 19: Molecular structure of complex 41–46 [88,89].
Figure 20: Molecular structure of asymmetric derivatives 47–49 based on triaryl-type of bridge [90].
Figure 21: Chemical structure of the asymmetric tetradentate derivatives 50 and 51 based on spirofluorene link...
Figure 22: Molecular structure of the pyridylazolate-based complexes 52–54 reported by Chi and co-workers [97].
Figure 23: Chemical structure of the red-to-NIR emitting complexes 55–57 bearing donor–acceptor triphenylamino...
Figure 24: Molecular structures of the Pt(IV) derivatives 58 and 59 employed as triplet emitters in solution-p...
Beilstein J. Org. Chem. 2018, 14, 1389–1412, doi:10.3762/bjoc.14.117
Graphical Abstract
Figure 1: Inherently chiral calix[4]arene-based phase-transfer catalysts.
Scheme 1: Asymmetric alkylations of 3 catalyzed by (±)-1 and (±)-2 under phase-transfer conditions.
Scheme 2: Synthesis of chiral calix[4]arene-based phase-transfer catalyst 7 and structure of O’Donnell’s N-be...
Scheme 3: Asymmetric alkylation of glycine derivative 3 catalyzed by calixarene-based phase-transfer catalyst ...
Figure 2: Calix[4]arene-amides used as phase-transfer catalysts.
Scheme 4: Phase-transfer alkylation of 3 catalyzed by calixarene-triamide 12.
Scheme 5: Synthesis of inherently chiral calix[4]arenes 20a/20b substituted at the lower rim. Reaction condit...
Scheme 6: Asymmetric Henry reaction between 21 and 22 catalyzed by 20a/20b.
Figure 3: Proposed transition state model of asymmetric Henry reaction.
Scheme 7: Synthesis of enantiomerically pure phosphinoferrocenyl-substituted calixarene ligands 27–29.
Scheme 8: Asymmetric coupling reaction of aryl boronates and aryl halides in the presence of calixarene mono ...
Scheme 9: Asymmetric allylic alkylation in the presence of calix[4]arene ligand (S,S)-29.
Figure 4: Structure of inherently chiral oxazoline calix[4]arenes applied in the palladium-catalyzed Tsuji–Tr...
Scheme 10: Asymmetric Tsuji–Trost reaction in the presence of calix[4]arene ligands 36–39.
Figure 5: BINOL-derived calix[4]arene-diphosphite ligands.
Scheme 11: Asymmetric hydrogenation of 41a and 41b catalyzed by in situ-generated catalysts comprised of [Rh(C...
Figure 6: Inherently chiral calix[4]arene 43 containing a diarylmethanol structure.
Scheme 12: Asymmetric Michael addition reaction of 44 with 45 catalyzed by 43.
Figure 7: Calix[4]arene-based chiral primary amine–thiourea catalysts.
Scheme 13: Asymmetric Michael addition of 48 with 49 catalyzed by 47a and 47b.
Scheme 14: Enantioselective Michael addition of 51 to 52 catalyzed by calix[4]arene thioureas.
Scheme 15: Synthesis of calix[4]arene-based tertiary amine–thioureas 54–56.
Scheme 16: Asymmetric Michael addition of 34 and 57 to nitroalkenes 49 catalyzed by 54b.
Scheme 17: Synthesis of p-tert-butylcalix[4]arene bis-squaramide derivative 64.
Scheme 18: Asymmetric Michael addition catalyzed by 64.
Scheme 19: Synthesis of chiral p-tert-butylphenol analogue 68.
Figure 8: Novel prolinamide organocatalysts based on the calix[4]arene scaffold.
Scheme 20: Asymmetric aldol reactions of 72 with 70 and 71 catalyzed by 69b.
Scheme 21: Synthesis of p-tert-butylcalix[4]arene-based chiral organocatalysts 75 and 78 derived from L-prolin...
Scheme 22: Synthesis of upper rim-functionalized calix[4]arene-based L-proline derivative 83.
Scheme 23: Synthesis and proposed structure of Calix-Pro-MN (86).
Figure 9: Calix[4]arene-based L-proline catalysts containing ester, amide and acid units.
Scheme 24: Synthesis of calix[4]arene-based prolinamide 92.
Scheme 25: Calixarene-based catalysts for the aldol reaction of 21 with 70.
Scheme 26: Asymmetric aldol reactions of 72 with cyclic ketones catalyzed by calix[4]arene-based chiral organo...
Figure 10: A proposed structure for catalyst 92 in H2O.
Scheme 27: Synthetic route for organocatalyst 98.
Scheme 28: Asymmetric aldol reactions catalyzed by 99.
Figure 11: Proposed catalytic environment for catalyst 99 in the presence of water.
Scheme 29: Asymmetric aldol reactions between 94 and 72 catalyzed by 55a.
Scheme 30: Enantioselective Biginelli reactions catalyzed by 69f.
Scheme 31: Synthesis of calix[4]arene–(salen) complexes.
Scheme 32: Enantioselective epoxidation of 108 catalyzed by 107a/107b.
Scheme 33: Synthesis of inherently chiral calix[4]arene catalysts 111 and 112.
Scheme 34: Enantioselective MPV reduction.
Scheme 35: Synthesis of chiral calix[4]arene ligands 116a–c.
Scheme 36: Asymmetric MPV reduction with chiral calix[4]arene ligands.
Scheme 37: Chiral AlIII–calixarene complexes bearing distally positioned chiral substituents.
Scheme 38: Asymmetric MPV reduction in the presence of chiral calix[4]arene diphosphites.
Scheme 39: Synthesis of enantiomerically pure inherently chiral calix[4]arene phosphonic acid.
Scheme 40: Asymmetric aza-Diels–Alder reactions catalyzed by (cR,pR)-121.
Scheme 41: Asymmetric ring opening of epoxides catalyzed by (cR,pR)-121.
Beilstein J. Org. Chem. 2018, 14, 1317–1348, doi:10.3762/bjoc.14.113
Graphical Abstract
Scheme 1: Thermal reaction of sydnones with symmetrical alkynes.
Scheme 2: Reaction of sydnones with strained cycloalkynes.
Scheme 3: Reaction of sydnones with didehydrobenzenes.
Scheme 4: Formation of isomeric pyrazole dicarboxylates.
Scheme 5: Mechanism of thermal cycloaddition between sydnones and alkynes.
Scheme 6: Mechanism of photochemical reaction of sydnones with symmetrical alkynes.
Scheme 7: HOMO–LUMO diagram for thermal [3 + 2]-cycloaddition of sydnones with alkynes.
Scheme 8: Synthetic strategy leading to 1,2-disubstituted pyrazoles.
Scheme 9: Unsuccessful reaction with phenylpropiolic acid.
Scheme 10: Synthetic strategy leading to 1,4,5-trisubstituted pyrazoles.
Scheme 11: Reaction of sydnones carrying in position 4- six-membered 2-N-heterocyclic ring.
Scheme 12: Strain-promoted sydnone alkyne cycloaddition (SPSAC).
Scheme 13: Synthesis of a key intermediate of niraparib.
Scheme 14: Reaction of sydnones with 1,3-/1,4-benzdiyne equivalents.
Scheme 15: Reaction of sydnones with heterocyclic strained cycloalkynes.
Scheme 16: Mono-copper catalyzed cycloaddition reaction.
Scheme 17: Di-copper catalyzed cycloaddition reaction.
Beilstein J. Org. Chem. 2018, 14, 1293–1308, doi:10.3762/bjoc.14.111
Graphical Abstract
Figure 1: Biological action of single-stranded oligonucleotides (ON): antigene and antisense pathways.
Figure 2: Selected examples 1–6 of nucleic acid modifications based on additionally attached positively charg...
Figure 3: Oligonucleotide analogues with artificial cationic backbone linkages discussed in this review: amin...
Scheme 1: Structure of Letsinger's modified deoxyadenosyl dinucleotide 11 and synthesis of cationic oligonucl...
Figure 4: Artificial cationic backbone linkages 19 and 20 which are structurally related to aminoalkylated ph...
Scheme 2: Bruice's synthesis of guanidinium-linked DNG oligomer 29 in the 5'→3' direction (Troc = 2,2,2-trich...
Scheme 3: Bruice's synthesis of purine-containing guanidinium-linked DNG oligomer 36 in the 3'→5' direction (...
Scheme 4: Bruice's synthesis of S-methylthiourea-linked DNmt oligomer 43.
Figure 5: Structure of the natural product muraymycin A1 (44) and design concept of nucleosyl amino acid (NAA...
Scheme 5: Retrosynthetic summary of Ducho's synthesis of partially zwitterionic NAA-modified oligonucleotides ...
Scheme 6: Retrosynthetic summary of Ducho's and Grossmann's synthesis of fully cationic NAA-modified oligonuc...
Beilstein J. Org. Chem. 2018, 14, 875–883, doi:10.3762/bjoc.14.74
Graphical Abstract
Scheme 1: Previously reported post-Ugi-4CR methods for the synthesis of 2-oxindoles and spirocyclic 2-oxindol...
Scheme 2: Post-Ugi-4CR/transamidation/cyclization sequence.
Scheme 3: Base-promoted intramolecular 5-endo-dig cyclization.
Figure 1: ORTEP diagram of compound 7a.
Figure 2: Readily and synthetically accessible starting materials.
Scheme 4: Reaction scope with varying combinations of substrates.
Scheme 5: Synthesis of 5-chloro-1'-phenylspiro[indoline-3,2'-pyrrolidine]-2,5'-dione (8a).
Figure 3: Small molecule library of spiro[indoline-3,2'-pyrrolidine]-2,5'-dione analogs.
Scheme 6: Method applicability for the one-pot synthesis of 5-HT6 receptor antagonist 8j [53].